Dana-Farber Cancer Institute
Avatar

Is it Time to Treat Patients with Smoldering Myeloma in 2018?

By Dana-Farber Cancer Institute FEATURING Irene Ghobrial
By Dana-Farber Cancer Institute FEATURING Irene Ghobrial
197 views
June 22, 2018
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Related Content

AUTOPLAY
19:08
Insights from 2023 ASH Annual Meeting

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…

Feat. R. Banerjee
28:20
PleXus Communications

Why We Should Not Treat SMM

Feat. B. Derman
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
11:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy &…

Feat. O. Landgren
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
32:06
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

Should Patients With High-Risk SMM Be Treated Outside a Clinical Tri…

Feat. M. Gertz
52:39
Yale Cancer Center

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Feat. A. Chari
22:15
5th SOHO Italy Annual Conference

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

Feat. K. Anderson
04:55
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering …

Feat. S. Thorsteinsdottir
21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
13:51
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait

Feat. A. Dispenzieri
10:09
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Feat. T. Martin
10:25
5th SOHO Italy Annual Conference

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

Feat. I. Ghobrial
32:49
PleXus Communications

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM

Feat. N. Antao, P. Hagen
07:20
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and …

Feat. O. Nadeem
10:36
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Immuno-PRISM Study of Bispecific Antibodies…

Feat. O. Nadeem
08:35
GRACE

Oncologists' Guidance on Treating Smoldering Myeloma: Panel Dis…

Feat. A. Goodman, A. Taneja, T. Phillips
14:03
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Smoldering MM - Personalized Time to Treat?

Feat. S. Lonial
14:52
5th SOHO Italy Annual Conference

SOHO Italy 2023: MM State-of-the-Art in the USA and Evolving Questio…

Feat. H. Lee
20:28
Dana-Farber Cancer Institute

The PROMISE of Early Detection and Interception in Myeloma

Feat. I. Ghobrial